Creative Planning
RYTM icon

Creative Planning’s Rhythm Pharmaceuticals RYTM Stock Holding History

Creative Planning’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Sell
21,085
-4,121
-16% -$401K ﹤0.01% 1964
2025
Q4 		$2.7M Buy
25,206
+261
+1% +$27.7K ﹤0.01% 1464
2025
Q3 		$2.52M Buy
24,945
+7,723
+45% +$717K ﹤0.01% 1354
2025
Q2 		$1.09M Buy
17,222
+4,889
+40% +$299K ﹤0.01% 1784
2025
Q1 		$653K Buy
12,333
+2,109
+21% +$117K ﹤0.01% 2063
2024
Q4 		$572K Buy
10,224
+1,630
+19% +$90K ﹤0.01% 2103
2024
Q3 		$450K Buy
+8,594
New +$412K ﹤0.01% 2199

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Creative Planning's RYTM Position: Q1 2026 in Review

Creative Planning reduced its Rhythm Pharmaceuticals (RYTM) stake by 16% in Q1 2026, selling an estimated $401K and leaving 21,085 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

Creative Planning first reported a position in RYTM in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.7M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Creative Planning held 21,085 shares of Rhythm Pharmaceuticals worth $1.83M as of Q1 2026.
  • Creative Planning sold 4,121 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $401K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1964 holding.
  • Creative Planning first reported a position in Rhythm Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Creative Planning's Rhythm Pharmaceuticals position peaked at $2.7M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.